| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2026-01-30 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | SELL | -248 @ USD 7.46999 | USD -1,853 | The ETF sold 248 shares of ARCT on 2026-01-30. The shares were previously bought for an average price of USD 10.8202. The Arcturus Therapeutics Holdings Inc shares were sold for -31.0% lower than average price of previous purchases. This resulted in an overall loss of USD 831 The average price that the ETF previously sold ARCT share for is USD 12.474 which is higher than the selling price of USD 7.46999 on 2026-01-30. |
| 4974.T - Takara Bio Inc. | SELL | -400 @ JPY 5.26384 | JPY -2,106 | The ETF sold 400 shares of 4974.T on 2026-01-30. The shares were previously bought for an average price of JPY 5.60044. The Takara Bio Inc. shares were sold for -6.0% lower than average price of previous purchases. This resulted in an overall loss of JPY 135 The average price that the ETF previously sold 4974.T share for is JPY 5.71923 which is higher than the selling price of JPY 5.26384 on 2026-01-30. |
| SLP - Sylvania Platinum Limited | SELL | -164 @ USD 16.89 | USD -2,770 | The ETF sold 164 shares of SLP on 2026-01-30. The shares were previously bought for an average price of USD 25.4848. The Sylvania Platinum Limited shares were sold for -33.7% lower than average price of previous purchases. This resulted in an overall loss of USD 1,410 The average price that the ETF previously sold SLP share for is USD 26.0667 which is higher than the selling price of USD 16.89 on 2026-01-30. |
| 4549.T - Eiken Chemical Co., Ltd. | SELL | -200 @ JPY 15.5063 | JPY -3,101 | The ETF sold 200 shares of 4549.T on 2026-01-30. The shares were previously bought for an average price of JPY 13.8284. The Eiken Chemical Co., Ltd. shares were sold for 12.1% higher than average price of previous purchases. This sale made a profit of JPY 336 The average price that the ETF previously sold 4549.T share for is JPY 14.3619 so the ETF has sold 200 shares on 2026-01-30 at a higher price than the previous selling average. |
| EVH - Evolent Health Inc | SELL | -1,152 @ USD 3.21 | USD -3,698 | The ETF sold 1152 shares of EVH on 2026-01-30. The shares were previously bought for an average price of USD 8.43957. The Evolent Health Inc shares were sold for -62.0% lower than average price of previous purchases. This resulted in an overall loss of USD 6,024 The average price that the ETF previously sold EVH share for is USD 10.0203 which is higher than the selling price of USD 3.21 on 2026-01-30. |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | SELL | -1,600 @ HKD 2.73762 | HKD -4,380 | The ETF sold 1600 shares of 1877.HK on 2026-01-30. The shares were previously bought for an average price of HKD 2.67899. The SHANGHAI JUNSHI BIOSCIENCES LTD H shares were sold for 2.2% higher than average price of previous purchases. This sale made a profit of HKD 94 The average price that the ETF previously sold 1877.HK share for is HKD 2.115 so the ETF has sold 1600 shares on 2026-01-30 at a higher price than the previous selling average. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -606 @ USD 7.54 | USD -4,569 | The ETF sold 606 shares of VNDA on 2026-01-30. The shares were previously bought for an average price of USD 5.79906. The Vanda Pharmaceuticals Inc shares were sold for 30.0% higher than average price of previous purchases. This sale made a profit of USD 1,055 The average price that the ETF previously sold VNDA share for is USD 4.80242 so the ETF has sold 606 shares on 2026-01-30 at a higher price than the previous selling average. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -1,402 @ USD 3.36 | USD -4,711 | The ETF sold 1402 shares of MRVI on 2026-01-30. The shares were previously bought for an average price of USD 3.04161. The Maravai Lifesciences Holdings Inc shares were sold for 10.5% higher than average price of previous purchases. This sale made a profit of USD 446 The average price that the ETF previously sold MRVI share for is USD 3.39186 which is higher than the selling price of USD 3.36 on 2026-01-30. |
| LAB - Standard Biotools Inc | SELL | -3,718 @ USD 1.4 | USD -5,205 | The ETF sold 3718 shares of LAB on 2026-01-30. The shares were previously bought for an average price of USD 1.38379. The Standard Biotools Inc shares were sold for 1.2% higher than average price of previous purchases. This sale made a profit of USD 60 The average price that the ETF previously sold LAB share for is USD 1.44508 which is higher than the selling price of USD 1.4 on 2026-01-30. |
| RGNX - Regenxbio Inc | SELL | -476 @ USD 11.16 | USD -5,312 | The ETF sold 476 shares of RGNX on 2026-01-30. The shares were previously bought for an average price of USD 9.29232. The Regenxbio Inc shares were sold for 20.1% higher than average price of previous purchases. This sale made a profit of USD 889 The average price that the ETF previously sold RGNX share for is USD 9.18946 so the ETF has sold 476 shares on 2026-01-30 at a higher price than the previous selling average. |
| MYGN - Myriad Genetics Inc | SELL | -974 @ USD 5.62 | USD -5,474 | The ETF sold 974 shares of MYGN on 2026-01-30. The shares were previously bought for an average price of USD 8.2372. The Myriad Genetics Inc shares were sold for -31.8% lower than average price of previous purchases. This resulted in an overall loss of USD 2,549 The average price that the ETF previously sold MYGN share for is USD 9.64908 which is higher than the selling price of USD 5.62 on 2026-01-30. |
| 7575.T - Japan Lifeline Co., Ltd. | SELL | -600 @ JPY 10.0156 | JPY -6,009 | The ETF sold 600 shares of 7575.T on 2026-01-30. The shares were previously bought for an average price of JPY 10.1599. The Japan Lifeline Co., Ltd. shares were sold for -1.4% lower than average price of previous purchases. This resulted in an overall loss of JPY 87 The average price that the ETF previously sold 7575.T share for is JPY 9.5972 so the ETF has sold 600 shares on 2026-01-30 at a higher price than the previous selling average. |
| EMBC - Embecta Corp | SELL | -614 @ USD 10.61 | USD -6,515 | The ETF sold 614 shares of EMBC on 2026-01-30. The shares were previously bought for an average price of USD 12.4848. The Embecta Corp shares were sold for -15.0% lower than average price of previous purchases. This resulted in an overall loss of USD 1,151 The average price that the ETF previously sold EMBC share for is USD 12.2083 which is higher than the selling price of USD 10.61 on 2026-01-30. |
| XVIVO.ST - | SELL | -260 @ SEK 25.4398 | SEK -6,614 | The ETF sold 260 shares of XVIVO.ST on 2026-01-30. The shares were previously bought for an average price of SEK 37.4926. The shares were sold for -32.1% lower than average price of previous purchases. This resulted in an overall loss of SEK 3,134 The average price that the ETF previously sold XVIVO.ST share for is SEK 31.8045 which is higher than the selling price of SEK 25.4398 on 2026-01-30. |
| VLA.PA - Valneva SE | SELL | -1,456 @ EUR 4.62536 | EUR -6,735 | The ETF sold 1456 shares of VLA.PA on 2026-01-30. The shares were previously bought for an average price of EUR 3.01716. The Valneva SE shares were sold for 53.3% higher than average price of previous purchases. This sale made a profit of EUR 2,342 The average price that the ETF previously sold VLA.PA share for is EUR 3.2534 so the ETF has sold 1456 shares on 2026-01-30 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -834 @ USD 8.12 | USD -6,772 | The ETF sold 834 shares of KURA on 2026-01-30. The shares were previously bought for an average price of USD 10.0287. The Kura Oncology Inc shares were sold for -19.0% lower than average price of previous purchases. This resulted in an overall loss of USD 1,592 The average price that the ETF previously sold KURA share for is USD 9.26133 which is higher than the selling price of USD 8.12 on 2026-01-30. |
| CTKB - Cytek Biosciences Inc | SELL | -1,396 @ USD 5 | USD -6,980 | The ETF sold 1396 shares of CTKB on 2026-01-30. The shares were previously bought for an average price of USD 5.65349. The Cytek Biosciences Inc shares were sold for -11.6% lower than average price of previous purchases. This resulted in an overall loss of USD 912 The average price that the ETF previously sold CTKB share for is USD 4.53057 so the ETF has sold 1396 shares on 2026-01-30 at a higher price than the previous selling average. |
| PACB - Pacific Biosciences of California | SELL | -3,206 @ USD 2.26 | USD -7,246 | The ETF sold 3206 shares of PACB on 2026-01-30. The shares were previously bought for an average price of USD 1.46365. The Pacific Biosciences of California shares were sold for 54.4% higher than average price of previous purchases. This sale made a profit of USD 2,553 The average price that the ETF previously sold PACB share for is USD 1.55249 so the ETF has sold 3206 shares on 2026-01-30 at a higher price than the previous selling average. |
| RO.SW - | SELL | -16 @ CHF 462.307 | CHF -7,397 | The ETF sold 16 shares of RO.SW on 2026-01-30. The shares were previously bought for an average price of CHF 378.413. The shares were sold for 22.2% higher than average price of previous purchases. This sale made a profit of CHF 1,342 The average price that the ETF previously sold RO.SW share for is CHF 337.325 so the ETF has sold 16 shares on 2026-01-30 at a higher price than the previous selling average. |
| IOVA - Iovance Biotherapeutics Inc | SELL | -2,942 @ USD 2.55 | USD -7,502 | The ETF sold 2942 shares of IOVA on 2026-01-30. The shares were previously bought for an average price of USD 2.43152. The Iovance Biotherapeutics Inc shares were sold for 4.9% higher than average price of previous purchases. This sale made a profit of USD 349 The average price that the ETF previously sold IOVA share for is USD 4.4631 which is higher than the selling price of USD 2.55 on 2026-01-30. |
| 096530.KQ - Seegene, Inc. | SELL | -384 @ KRW 19.8694 | KRW -7,630 | The ETF sold 384 shares of 096530.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 17.2899. The Seegene, Inc. shares were sold for 14.9% higher than average price of previous purchases. This sale made a profit of KRW 991 The average price that the ETF previously sold 096530.KQ share for is KRW 20.6461 which is higher than the selling price of KRW 19.8694 on 2026-01-30. |
| 328130.KQ - Lunit Inc. | SELL | -282 @ KRW 27.9283 | KRW -7,876 | The ETF sold 282 shares of 328130.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 35.4304. The Lunit Inc. shares were sold for -21.2% lower than average price of previous purchases. This resulted in an overall loss of KRW 2,116 The average price that the ETF previously sold 328130.KQ share for is KRW 34.8118 which is higher than the selling price of KRW 27.9283 on 2026-01-30. |
| VIR - Vir Biotechnology Inc | SELL | -1,078 @ USD 7.44 | USD -8,020 | The ETF sold 1078 shares of VIR on 2026-01-30. The shares were previously bought for an average price of USD 6.97311. The Vir Biotechnology Inc shares were sold for 6.7% higher than average price of previous purchases. This sale made a profit of USD 503 The average price that the ETF previously sold VIR share for is USD 6.4236 so the ETF has sold 1078 shares on 2026-01-30 at a higher price than the previous selling average. |
| VIR - Vidrala S.A | SELL | -1,078 @ USD 7.44 | USD -8,020 | The ETF sold 1078 shares of VIR on 2026-01-30. The shares were previously bought for an average price of USD 6.97311. The Vidrala S.A shares were sold for 6.7% higher than average price of previous purchases. This sale made a profit of USD 503 The average price that the ETF previously sold VIR share for is USD 6.4236 so the ETF has sold 1078 shares on 2026-01-30 at a higher price than the previous selling average. |
| EUZ.DE - Eckert & Ziegler SE | SELL | -456 @ EUR 17.8091 | EUR -8,121 | The ETF sold 456 shares of EUZ.DE on 2026-01-30. The shares were previously bought for an average price of EUR 18.5221. The Eckert & Ziegler SE shares were sold for -3.8% lower than average price of previous purchases. This resulted in an overall loss of EUR 325 The average price that the ETF previously sold EUZ.DE share for is EUR 22.6312 which is higher than the selling price of EUR 17.8091 on 2026-01-30. |
| JANX - Janux Therapeutics Inc | SELL | -608 @ USD 13.71 | USD -8,336 | The ETF sold 608 shares of JANX on 2026-01-30. The shares were previously bought for an average price of USD 24.2014. The Janux Therapeutics Inc shares were sold for -43.4% lower than average price of previous purchases. This resulted in an overall loss of USD 6,379 The average price that the ETF previously sold JANX share for is USD 30.837 which is higher than the selling price of USD 13.71 on 2026-01-30. |
| IART - Integra LifeSciences Holdings | SELL | -772 @ USD 11.14 | USD -8,600 | The ETF sold 772 shares of IART on 2026-01-30. The shares were previously bought for an average price of USD 15.5324. The Integra LifeSciences Holdings shares were sold for -28.3% lower than average price of previous purchases. This resulted in an overall loss of USD 3,391 The average price that the ETF previously sold IART share for is USD 17.9141 which is higher than the selling price of USD 11.14 on 2026-01-30. |
| ABCL - Abcellera Biologics Inc | SELL | -2,440 @ USD 3.62 | USD -8,833 | The ETF sold 2440 shares of ABCL on 2026-01-30. The shares were previously bought for an average price of USD 3.67532. The Abcellera Biologics Inc shares were sold for -1.5% lower than average price of previous purchases. This resulted in an overall loss of USD 135 The average price that the ETF previously sold ABCL share for is USD 2.81521 so the ETF has sold 2440 shares on 2026-01-30 at a higher price than the previous selling average. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -808 @ USD 11.16 | USD -9,017 | The ETF sold 808 shares of DAWN on 2026-01-30. The shares were previously bought for an average price of USD 9.52558. The Day One Biopharmaceuticals Inc shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of USD 1,321 The average price that the ETF previously sold DAWN share for is USD 8.24615 so the ETF has sold 808 shares on 2026-01-30 at a higher price than the previous selling average. |
| SDGR - Schrodinger Inc | SELL | -652 @ USD 13.97 | USD -9,108 | The ETF sold 652 shares of SDGR on 2026-01-30. The shares were previously bought for an average price of USD 20.2044. The Schrodinger Inc shares were sold for -30.9% lower than average price of previous purchases. This resulted in an overall loss of USD 4,065 The average price that the ETF previously sold SDGR share for is USD 20.5415 which is higher than the selling price of USD 13.97 on 2026-01-30. |
| 302440.KS - SK BIOSCIENCE LTD | SELL | -274 @ KRW 35.223 | KRW -9,651 | The ETF sold 274 shares of 302440.KS on 2026-01-30. The shares were previously bought for an average price of KRW 35.7815. The SK BIOSCIENCE LTD shares were sold for -1.6% lower than average price of previous purchases. This resulted in an overall loss of KRW 153 The average price that the ETF previously sold 302440.KS share for is KRW 31.5743 so the ETF has sold 274 shares on 2026-01-30 at a higher price than the previous selling average. |
| ASTH - Astrana Health Inc | SELL | -426 @ USD 22.74 | USD -9,687 | The ETF sold 426 shares of ASTH on 2026-01-30. The shares were previously bought for an average price of USD 26.6318. The Astrana Health Inc shares were sold for -14.6% lower than average price of previous purchases. This resulted in an overall loss of USD 1,658 The average price that the ETF previously sold ASTH share for is USD 32.7924 which is higher than the selling price of USD 22.74 on 2026-01-30. |
| 007390.KQ - NatureCell Co.,Ltd. | SELL | -556 @ KRW 17.542 | KRW -9,753 | The ETF sold 556 shares of 007390.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 21.1396. The NatureCell Co.,Ltd. shares were sold for -17.0% lower than average price of previous purchases. This resulted in an overall loss of KRW 2,000 The average price that the ETF previously sold 007390.KQ share for is KRW 16.5452 so the ETF has sold 556 shares on 2026-01-30 at a higher price than the previous selling average. |
| ARVN - Arvinas Inc | SELL | -744 @ USD 13.38 | USD -9,955 | The ETF sold 744 shares of ARVN on 2026-01-30. The shares were previously bought for an average price of USD 11.4578. The Arvinas Inc shares were sold for 16.8% higher than average price of previous purchases. This sale made a profit of USD 1,430 The average price that the ETF previously sold ARVN share for is USD 12.8527 so the ETF has sold 744 shares on 2026-01-30 at a higher price than the previous selling average. |
| 4587.T - PeptiDream Inc. | SELL | -1,000 @ JPY 10.1387 | JPY -10,139 | The ETF sold 1000 shares of 4587.T on 2026-01-30. The shares were previously bought for an average price of JPY 10.975. The PeptiDream Inc. shares were sold for -7.6% lower than average price of previous purchases. This resulted in an overall loss of JPY 836 The average price that the ETF previously sold 4587.T share for is JPY 10.7018 which is higher than the selling price of JPY 10.1387 on 2026-01-30. |
| ANAB - AnaptysBio Inc | SELL | -226 @ USD 47.41 | USD -10,715 | The ETF sold 226 shares of ANAB on 2026-01-30. The shares were previously bought for an average price of USD 25.5396. The AnaptysBio Inc shares were sold for 85.6% higher than average price of previous purchases. This sale made a profit of USD 4,943 The average price that the ETF previously sold ANAB share for is USD 24.6501 so the ETF has sold 226 shares on 2026-01-30 at a higher price than the previous selling average. |
| BLFS - BioLife Solutions Inc | SELL | -494 @ USD 21.8 | USD -10,769 | The ETF sold 494 shares of BLFS on 2026-01-30. The shares were previously bought for an average price of USD 25.3348. The BioLife Solutions Inc shares were sold for -14.0% lower than average price of previous purchases. This resulted in an overall loss of USD 1,746 The average price that the ETF previously sold BLFS share for is USD 24.7287 which is higher than the selling price of USD 21.8 on 2026-01-30. |
| CERT - Certara Inc | SELL | -1,232 @ USD 8.79 | USD -10,829 | The ETF sold 1232 shares of CERT on 2026-01-30. The shares were previously bought for an average price of USD 10.2768. The Certara Inc shares were sold for -14.5% lower than average price of previous purchases. This resulted in an overall loss of USD 1,832 The average price that the ETF previously sold CERT share for is USD 10.6596 which is higher than the selling price of USD 8.79 on 2026-01-30. |
| AMLX - Amylyx Pharmaceuticals Inc | SELL | -778 @ USD 14.29 | USD -11,118 | The ETF sold 778 shares of AMLX on 2026-01-30. The shares were previously bought for an average price of USD 13.5867. The Amylyx Pharmaceuticals Inc shares were sold for 5.2% higher than average price of previous purchases. This sale made a profit of USD 547 The average price that the ETF previously sold AMLX share for is USD 11.1515 so the ETF has sold 778 shares on 2026-01-30 at a higher price than the previous selling average. |
| CDNA - Caredx Inc | SELL | -542 @ USD 20.55 | USD -11,138 | The ETF sold 542 shares of CDNA on 2026-01-30. The shares were previously bought for an average price of USD 19.2653. The Caredx Inc shares were sold for 6.7% higher than average price of previous purchases. This sale made a profit of USD 696 The average price that the ETF previously sold CDNA share for is USD 19.5139 so the ETF has sold 542 shares on 2026-01-30 at a higher price than the previous selling average. |
| DYVOX.ST - | SELL | -1,142 @ SEK 9.88449 | SEK -11,288 | The ETF sold 1142 shares of DYVOX.ST on 2026-01-30. The shares were previously bought for an average price of SEK 7.64532. The shares were sold for 29.3% higher than average price of previous purchases. This sale made a profit of SEK 2,557 The average price that the ETF previously sold DYVOX.ST share for is SEK 7.76574 so the ETF has sold 1142 shares on 2026-01-30 at a higher price than the previous selling average. |
| EVT.DE - Evotec SE | SELL | -1,582 @ EUR 7.39724 | EUR -11,702 | The ETF sold 1582 shares of EVT.DE on 2026-01-30. The shares were previously bought for an average price of EUR 6.65945. The Evotec SE shares were sold for 11.1% higher than average price of previous purchases. This sale made a profit of EUR 1,167 The average price that the ETF previously sold EVT.DE share for is EUR 7.80513 which is higher than the selling price of EUR 7.39724 on 2026-01-30. |
| CSTL - Castle Biosciences Inc | SELL | -304 @ USD 39.39 | USD -11,975 | The ETF sold 304 shares of CSTL on 2026-01-30. The shares were previously bought for an average price of USD 23.8365. The Castle Biosciences Inc shares were sold for 65.3% higher than average price of previous purchases. This sale made a profit of USD 4,728 The average price that the ETF previously sold CSTL share for is USD 25.3968 so the ETF has sold 304 shares on 2026-01-30 at a higher price than the previous selling average. |
| RLAY - Relay Therapeutics Inc | SELL | -1,574 @ USD 7.66 | USD -12,057 | The ETF sold 1574 shares of RLAY on 2026-01-30. The shares were previously bought for an average price of USD 7.15494. The Relay Therapeutics Inc shares were sold for 7.1% higher than average price of previous purchases. This sale made a profit of USD 795 The average price that the ETF previously sold RLAY share for is USD 4.37227 so the ETF has sold 1574 shares on 2026-01-30 at a higher price than the previous selling average. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -538 @ USD 22.53 | USD -12,121 | The ETF sold 538 shares of ZYME on 2026-01-30. The shares were previously bought for an average price of USD 19.9916. The Zymeworks Inc. Common Stock shares were sold for 12.7% higher than average price of previous purchases. This sale made a profit of USD 1,366 The average price that the ETF previously sold ZYME share for is USD 13.6119 so the ETF has sold 538 shares on 2026-01-30 at a higher price than the previous selling average. |
| ONT.L - Oxford Nanopore Technologies Ltd | SELL | -6,042 @ GBP 2.12699 | GBP -12,851 | The ETF sold 6042 shares of ONT.L on 2026-01-30. The shares were previously bought for an average price of GBP 1.81535. The Oxford Nanopore Technologies Ltd shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of GBP 1,883 The average price that the ETF previously sold ONT.L share for is GBP 1.62197 so the ETF has sold 6042 shares on 2026-01-30 at a higher price than the previous selling average. |
| PHM.MC - Pharma Mar SA | SELL | -142 @ EUR 93.9229 | EUR -13,337 | The ETF sold 142 shares of PHM.MC on 2026-01-30. The shares were previously bought for an average price of EUR 88.2649. The Pharma Mar SA shares were sold for 6.4% higher than average price of previous purchases. This sale made a profit of EUR 803 The average price that the ETF previously sold PHM.MC share for is EUR 85.6775 so the ETF has sold 142 shares on 2026-01-30 at a higher price than the previous selling average. |
| GLPG.AS - Galapagos NV | SELL | -398 @ EUR 33.8336 | EUR -13,466 | The ETF sold 398 shares of GLPG.AS on 2026-01-30. The shares were previously bought for an average price of EUR 30.5298. The Galapagos NV shares were sold for 10.8% higher than average price of previous purchases. This sale made a profit of EUR 1,315 The average price that the ETF previously sold GLPG.AS share for is EUR 27.3007 so the ETF has sold 398 shares on 2026-01-30 at a higher price than the previous selling average. |
| 039200.KQ - Oscotec Inc. | SELL | -352 @ KRW 38.6272 | KRW -13,597 | The ETF sold 352 shares of 039200.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 21.7161. The Oscotec Inc. shares were sold for 77.9% higher than average price of previous purchases. This sale made a profit of KRW 5,953 The average price that the ETF previously sold 039200.KQ share for is KRW 31.6353 so the ETF has sold 352 shares on 2026-01-30 at a higher price than the previous selling average. |
| NVCR - Novocure Ltd | SELL | -1,106 @ USD 12.4 | USD -13,714 | The ETF sold 1106 shares of NVCR on 2026-01-30. The shares were previously bought for an average price of USD 15.9386. The Novocure Ltd shares were sold for -22.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,914 The average price that the ETF previously sold NVCR share for is USD 17.1186 which is higher than the selling price of USD 12.4 on 2026-01-30. |
| NUVB - Nuvation Bio Inc | SELL | -2,644 @ USD 5.24 | USD -13,855 | The ETF sold 2644 shares of NUVB on 2026-01-30. The shares were previously bought for an average price of USD 7.81193. The Nuvation Bio Inc shares were sold for -32.9% lower than average price of previous purchases. This resulted in an overall loss of USD 6,800 The average price that the ETF previously sold NUVB share for is USD 6.38475 which is higher than the selling price of USD 5.24 on 2026-01-30. |
| NVAX - Novavax Inc | SELL | -1,588 @ USD 8.845 | USD -14,046 | The ETF sold 1588 shares of NVAX on 2026-01-30. The shares were previously bought for an average price of USD 6.61187. The Novavax Inc shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 3,546 The average price that the ETF previously sold NVAX share for is USD 7.16464 so the ETF has sold 1588 shares on 2026-01-30 at a higher price than the previous selling average. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -1,588 @ USD 8.845 | USD -14,046 | The ETF sold 1588 shares of NVAX on 2026-01-30. The shares were previously bought for an average price of USD 6.61187. The Hana Microelectronics Public Company Limited shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 3,546 The average price that the ETF previously sold NVAX share for is USD 7.16464 so the ETF has sold 1588 shares on 2026-01-30 at a higher price than the previous selling average. |
| 2162.HK - KEYMED BIOSCIENCES INC | SELL | -2,000 @ HKD 7.12575 | HKD -14,252 | The ETF sold 2000 shares of 2162.HK on 2026-01-30. The shares were previously bought for an average price of HKD 5.51394. The KEYMED BIOSCIENCES INC shares were sold for 29.2% higher than average price of previous purchases. This sale made a profit of HKD 3,224 The average price that the ETF previously sold 2162.HK share for is HKD 5.64337 so the ETF has sold 2000 shares on 2026-01-30 at a higher price than the previous selling average. |
| TNDM - Tandem Diabetes Care Inc | SELL | -722 @ USD 19.89 | USD -14,361 | The ETF sold 722 shares of TNDM on 2026-01-30. The shares were previously bought for an average price of USD 21.211. The Tandem Diabetes Care Inc shares were sold for -6.2% lower than average price of previous purchases. This resulted in an overall loss of USD 954 The average price that the ETF previously sold TNDM share for is USD 23.061 which is higher than the selling price of USD 19.89 on 2026-01-30. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | SELL | -4,000 @ HKD 3.61346 | HKD -14,454 | The ETF sold 4000 shares of 2252.HK on 2026-01-30. The shares were previously bought for an average price of HKD 3.21365. The SHANGHAI MICROPORT MEDBOT CLASS H shares were sold for 12.4% higher than average price of previous purchases. This sale made a profit of HKD 1,599 The average price that the ETF previously sold 2252.HK share for is HKD 2.73616 so the ETF has sold 4000 shares on 2026-01-30 at a higher price than the previous selling average. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -2,258 @ USD 6.58 | USD -14,858 | The ETF sold 2258 shares of BCRX on 2026-01-30. The shares were previously bought for an average price of USD 7.69136. The BioCryst Pharmaceuticals Inc shares were sold for -14.4% lower than average price of previous purchases. This resulted in an overall loss of USD 2,509 The average price that the ETF previously sold BCRX share for is USD 7.86664 which is higher than the selling price of USD 6.58 on 2026-01-30. |
| PHARM.AS - Pharming Group NV | SELL | -7,312 @ EUR 2.03668 | EUR -14,892 | The ETF sold 7312 shares of PHARM.AS on 2026-01-30. The shares were previously bought for an average price of EUR 1.013. The Pharming Group NV shares were sold for 101.1% higher than average price of previous purchases. This sale made a profit of EUR 7,485 The average price that the ETF previously sold PHARM.AS share for is EUR 1.001 so the ETF has sold 7312 shares on 2026-01-30 at a higher price than the previous selling average. |
| IBRX - Immunitybio Inc | SELL | -2,412 @ USD 6.25 | USD -15,075 | The ETF sold 2412 shares of IBRX on 2026-01-30. The shares were previously bought for an average price of USD 2.8933. The Immunitybio Inc shares were sold for 116.0% higher than average price of previous purchases. This sale made a profit of USD 8,096 The average price that the ETF previously sold IBRX share for is USD 3.15704 so the ETF has sold 2412 shares on 2026-01-30 at a higher price than the previous selling average. |
| 237690.KQ - ST Pharm Co.,Ltd. | SELL | -138 @ KRW 110.88 | KRW -15,301 | The ETF sold 138 shares of 237690.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 62.1333. The ST Pharm Co.,Ltd. shares were sold for 78.5% higher than average price of previous purchases. This sale made a profit of KRW 6,727 The average price that the ETF previously sold 237690.KQ share for is KRW 61.843 so the ETF has sold 138 shares on 2026-01-30 at a higher price than the previous selling average. |
| 4887.T - Sawai Group Holdings Co., Ltd. | SELL | -1,000 @ JPY 15.3637 | JPY -15,364 | The ETF sold 1000 shares of 4887.T on 2026-01-30. The shares were previously bought for an average price of JPY 13.8148. The Sawai Group Holdings Co., Ltd. shares were sold for 11.2% higher than average price of previous purchases. This sale made a profit of JPY 1,549 The average price that the ETF previously sold 4887.T share for is JPY 12.9263 so the ETF has sold 1000 shares on 2026-01-30 at a higher price than the previous selling average. |
| BIOA-B.ST - | SELL | -430 @ SEK 36.036 | SEK -15,495 | The ETF sold 430 shares of BIOA-B.ST on 2026-01-30. The shares were previously bought for an average price of SEK 30.8459. The shares were sold for 16.8% higher than average price of previous purchases. This sale made a profit of SEK 2,232 The average price that the ETF previously sold BIOA-B.ST share for is SEK 22.3698 so the ETF has sold 430 shares on 2026-01-30 at a higher price than the previous selling average. |
| NEU.AX - | SELL | -1,372 @ AUD 11.6922 | AUD -16,042 | The ETF sold 1372 shares of NEU.AX on 2026-01-30. The shares were previously bought for an average price of AUD 9.32504. The shares were sold for 25.4% higher than average price of previous purchases. This sale made a profit of AUD 3,248 The average price that the ETF previously sold NEU.AX share for is AUD 8.76053 so the ETF has sold 1372 shares on 2026-01-30 at a higher price than the previous selling average. |
| AXGN - Axogen Inc | SELL | -462 @ USD 34.85 | USD -16,101 | The ETF sold 462 shares of AXGN on 2026-01-30. The shares were previously bought for an average price of USD 20.2186. The Axogen Inc shares were sold for 72.4% higher than average price of previous purchases. This sale made a profit of USD 6,760 The average price that the ETF previously sold AXGN share for is USD 17.0965 so the ETF has sold 462 shares on 2026-01-30 at a higher price than the previous selling average. |
| FTRE - Fortrea Holdings Inc. | SELL | -972 @ USD 16.81 | USD -16,339 | The ETF sold 972 shares of FTRE on 2026-01-30. The shares were previously bought for an average price of USD 11.759. The Fortrea Holdings Inc. shares were sold for 43.0% higher than average price of previous purchases. This sale made a profit of USD 4,910 The average price that the ETF previously sold FTRE share for is USD 11.6323 so the ETF has sold 972 shares on 2026-01-30 at a higher price than the previous selling average. |
| RCUS - Arcus Biosciences Inc | SELL | -802 @ USD 21.04 | USD -16,874 | The ETF sold 802 shares of RCUS on 2026-01-30. The shares were previously bought for an average price of USD 10.6985. The Arcus Biosciences Inc shares were sold for 96.7% higher than average price of previous purchases. This sale made a profit of USD 8,294 The average price that the ETF previously sold RCUS share for is USD 13.5503 so the ETF has sold 802 shares on 2026-01-30 at a higher price than the previous selling average. |
| HRMY - Harmony Biosciences Holdings | SELL | -480 @ USD 36.52 | USD -17,530 | The ETF sold 480 shares of HRMY on 2026-01-30. The shares were previously bought for an average price of USD 33.9009. The Harmony Biosciences Holdings shares were sold for 7.7% higher than average price of previous purchases. This sale made a profit of USD 1,257 The average price that the ETF previously sold HRMY share for is USD 33.1078 so the ETF has sold 480 shares on 2026-01-30 at a higher price than the previous selling average. |
| STOK - Stoke Therapeutics Inc | SELL | -588 @ USD 30.34 | USD -17,840 | The ETF sold 588 shares of STOK on 2026-01-30. The shares were previously bought for an average price of USD 14.0152. The Stoke Therapeutics Inc shares were sold for 116.5% higher than average price of previous purchases. This sale made a profit of USD 9,599 The average price that the ETF previously sold STOK share for is USD 15.8911 so the ETF has sold 588 shares on 2026-01-30 at a higher price than the previous selling average. |
| CHEMM.CO - | SELL | -184 @ DKK 97.0974 | DKK -17,866 | The ETF sold 184 shares of CHEMM.CO on 2026-01-30. The shares were previously bought for an average price of DKK 82.8448. The shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of DKK 2,622 The average price that the ETF previously sold CHEMM.CO share for is DKK 78.0023 so the ETF has sold 184 shares on 2026-01-30 at a higher price than the previous selling average. |
| 13.HK - HUTCHMED (CHINA) LTD | SELL | -6,000 @ HKD 2.99371 | HKD -17,962 | The ETF sold 6000 shares of 13.HK on 2026-01-30. The shares were previously bought for an average price of HKD 2.99975. The HUTCHMED (CHINA) LTD shares were sold for -0.2% lower than average price of previous purchases. This resulted in an overall loss of HKD 36 The average price that the ETF previously sold 13.HK share for is HKD 3.04098 which is higher than the selling price of HKD 2.99371 on 2026-01-30. |
| RXRX - Recursion Pharmaceuticals Inc | SELL | -4,308 @ USD 4.19 | USD -18,051 | The ETF sold 4308 shares of RXRX on 2026-01-30. The shares were previously bought for an average price of USD 5.07031. The Recursion Pharmaceuticals Inc shares were sold for -17.4% lower than average price of previous purchases. This resulted in an overall loss of USD 3,792 The average price that the ETF previously sold RXRX share for is USD 5.33623 which is higher than the selling price of USD 4.19 on 2026-01-30. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | SELL | -12,000 @ HKD 1.52375 | HKD -18,285 | The ETF sold 12000 shares of 3933.HK on 2026-01-30. The shares were previously bought for an average price of HKD 1.6406. The THE UNITED LABORATORIES INTERNATIO shares were sold for -7.1% lower than average price of previous purchases. This resulted in an overall loss of HKD 1,402 The average price that the ETF previously sold 3933.HK share for is HKD 1.60159 which is higher than the selling price of HKD 1.52375 on 2026-01-30. |
| ATRC - AtriCure Inc | SELL | -518 @ USD 36.93 | USD -19,130 | The ETF sold 518 shares of ATRC on 2026-01-30. The shares were previously bought for an average price of USD 34.5694. The AtriCure Inc shares were sold for 6.8% higher than average price of previous purchases. This sale made a profit of USD 1,223 The average price that the ETF previously sold ATRC share for is USD 34.4678 so the ETF has sold 518 shares on 2026-01-30 at a higher price than the previous selling average. |
| QDEL - Quidel Corporation | SELL | -724 @ USD 27.17 | USD -19,671 | The ETF sold 724 shares of QDEL on 2026-01-30. The shares were previously bought for an average price of USD 29.5597. The Quidel Corporation shares were sold for -8.1% lower than average price of previous purchases. This resulted in an overall loss of USD 1,730 The average price that the ETF previously sold QDEL share for is USD 32.1582 which is higher than the selling price of USD 27.17 on 2026-01-30. |
| HLUN-B.CO - | SELL | -2,934 @ DKK 6.71 | DKK -19,687 | The ETF sold 2934 shares of HLUN-B.CO on 2026-01-30. The shares were previously bought for an average price of DKK 6.33828. The shares were sold for 5.9% higher than average price of previous purchases. This sale made a profit of DKK 1,091 The average price that the ETF previously sold HLUN-B.CO share for is DKK 5.44769 so the ETF has sold 2934 shares on 2026-01-30 at a higher price than the previous selling average. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -454 @ USD 43.92 | USD -19,940 | The ETF sold 454 shares of KNSA on 2026-01-30. The shares were previously bought for an average price of USD 40.7465. The Kiniksa Pharmaceuticals Ltd shares were sold for 7.8% higher than average price of previous purchases. This sale made a profit of USD 1,441 The average price that the ETF previously sold KNSA share for is USD 38.8163 so the ETF has sold 454 shares on 2026-01-30 at a higher price than the previous selling average. |
| DVAX - Dynavax Technologies Corporation | SELL | -1,288 @ USD 15.485 | USD -19,945 | The ETF sold 1288 shares of DVAX on 2026-01-30. The shares were previously bought for an average price of USD 13.8172. The Dynavax Technologies Corporation shares were sold for 12.1% higher than average price of previous purchases. This sale made a profit of USD 2,148 The average price that the ETF previously sold DVAX share for is USD 11.1871 so the ETF has sold 1288 shares on 2026-01-30 at a higher price than the previous selling average. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -1,390 @ USD 14.53 | USD -20,197 | The ETF sold 1390 shares of AUPH on 2026-01-30. The shares were previously bought for an average price of USD 12.7166. The Aurinia Pharmaceuticals Inc shares were sold for 14.3% higher than average price of previous purchases. This sale made a profit of USD 2,521 The average price that the ETF previously sold AUPH share for is USD 9.26715 so the ETF has sold 1390 shares on 2026-01-30 at a higher price than the previous selling average. |
| SRPT - Sarepta Therapeutics Inc | SELL | -1,050 @ USD 20.34 | USD -21,357 | The ETF sold 1050 shares of SRPT on 2026-01-30. The shares were previously bought for an average price of USD 41.9008. The Sarepta Therapeutics Inc shares were sold for -51.5% lower than average price of previous purchases. This resulted in an overall loss of USD 22,639 The average price that the ETF previously sold SRPT share for is USD 62.3243 which is higher than the selling price of USD 20.34 on 2026-01-30. |
| 9995.HK - REMEGEN LTD H | SELL | -2,000 @ HKD 10.7815 | HKD -21,563 | The ETF sold 2000 shares of 9995.HK on 2026-01-30. The shares were previously bought for an average price of HKD 10.1181. The REMEGEN LTD H shares were sold for 6.6% higher than average price of previous purchases. This sale made a profit of HKD 1,327 The average price that the ETF previously sold 9995.HK share for is HKD 4.78034 so the ETF has sold 2000 shares on 2026-01-30 at a higher price than the previous selling average. |
| CRVL - CorVel Corp | SELL | -310 @ USD 69.63 | USD -21,585 | The ETF sold 310 shares of CRVL on 2026-01-30. The shares were previously bought for an average price of USD 110.425. The CorVel Corp shares were sold for -36.9% lower than average price of previous purchases. This resulted in an overall loss of USD 12,646 The average price that the ETF previously sold CRVL share for is USD 127.491 which is higher than the selling price of USD 69.63 on 2026-01-30. |
| NEOG - Neogen Corporation | SELL | -2,252 @ USD 10.22 | USD -23,015 | The ETF sold 2252 shares of NEOG on 2026-01-30. The shares were previously bought for an average price of USD 9.65556. The Neogen Corporation shares were sold for 5.8% higher than average price of previous purchases. This sale made a profit of USD 1,271 The average price that the ETF previously sold NEOG share for is USD 8.89691 so the ETF has sold 2252 shares on 2026-01-30 at a higher price than the previous selling average. |
| TECN.SW - | SELL | -134 @ CHF 176.612 | CHF -23,666 | The ETF sold 134 shares of TECN.SW on 2026-01-30. The shares were previously bought for an average price of CHF 191.509. The shares were sold for -7.8% lower than average price of previous purchases. This resulted in an overall loss of CHF 1,996 The average price that the ETF previously sold TECN.SW share for is CHF 201.306 which is higher than the selling price of CHF 176.612 on 2026-01-30. |
| DIA.MI - DiaSorin SpA | SELL | -280 @ EUR 85.8689 | EUR -24,043 | The ETF sold 280 shares of DIA.MI on 2026-01-30. The shares were previously bought for an average price of EUR 64.1129. The DiaSorin SpA shares were sold for 33.9% higher than average price of previous purchases. This sale made a profit of EUR 6,092 The average price that the ETF previously sold DIA.MI share for is EUR 105.732 which is higher than the selling price of EUR 85.8689 on 2026-01-30. |
| TXG - 10X Genomics Inc | SELL | -1,192 @ USD 20.2 | USD -24,078 | The ETF sold 1192 shares of TXG on 2026-01-30. The shares were previously bought for an average price of USD 14.1607. The 10X Genomics Inc shares were sold for 42.6% higher than average price of previous purchases. This sale made a profit of USD 7,199 The average price that the ETF previously sold TXG share for is USD 11.854 so the ETF has sold 1192 shares on 2026-01-30 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -1,192 @ USD 20.2 | USD -24,078 | The ETF sold 1192 shares of TXG on 2026-01-30. The shares were previously bought for an average price of USD 14.1607. The Terex Corporation shares were sold for 42.6% higher than average price of previous purchases. This sale made a profit of USD 7,199 The average price that the ETF previously sold TXG share for is USD 11.854 so the ETF has sold 1192 shares on 2026-01-30 at a higher price than the previous selling average. |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | SELL | -294 @ KRW 81.9786 | KRW -24,102 | The ETF sold 294 shares of 326030.KS on 2026-01-30. The shares were previously bought for an average price of KRW 79.2638. The SK BIOPHARMACEUTICALS LTD shares were sold for 3.4% higher than average price of previous purchases. This sale made a profit of KRW 798 The average price that the ETF previously sold 326030.KS share for is KRW 74.2505 so the ETF has sold 294 shares on 2026-01-30 at a higher price than the previous selling average. |
| 6951.T - JEOL Ltd. | SELL | -600 @ JPY 40.2437 | JPY -24,146 | The ETF sold 600 shares of 6951.T on 2026-01-30. The shares were previously bought for an average price of JPY 33.4591. The JEOL Ltd. shares were sold for 20.3% higher than average price of previous purchases. This sale made a profit of JPY 4,071 The average price that the ETF previously sold 6951.T share for is JPY 32.2643 so the ETF has sold 600 shares on 2026-01-30 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -590 @ USD 41.07 | USD -24,231 | The ETF sold 590 shares of TWST on 2026-01-30. The shares were previously bought for an average price of USD 36.5506. The Twist Bioscience Corp shares were sold for 12.4% higher than average price of previous purchases. This sale made a profit of USD 2,666 The average price that the ETF previously sold TWST share for is USD 37.6657 so the ETF has sold 590 shares on 2026-01-30 at a higher price than the previous selling average. |
| EKTA-B.ST - | SELL | -3,902 @ SEK 6.46163 | SEK -25,213 | The ETF sold 3902 shares of EKTA-B.ST on 2026-01-30. The shares were previously bought for an average price of SEK 5.82449. The shares were sold for 10.9% higher than average price of previous purchases. This sale made a profit of SEK 2,486 The average price that the ETF previously sold EKTA-B.ST share for is SEK 5.22585 so the ETF has sold 3902 shares on 2026-01-30 at a higher price than the previous selling average. |
| BAVA.CO - | SELL | -826 @ DKK 30.5869 | DKK -25,265 | The ETF sold 826 shares of BAVA.CO on 2026-01-30. The shares were previously bought for an average price of DKK 26.2839. The shares were sold for 16.4% higher than average price of previous purchases. This sale made a profit of DKK 3,554 The average price that the ETF previously sold BAVA.CO share for is DKK 26.2345 so the ETF has sold 826 shares on 2026-01-30 at a higher price than the previous selling average. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -596 @ USD 48.16 | USD -28,703 | The ETF sold 596 shares of SUPN on 2026-01-30. The shares were previously bought for an average price of USD 40.6241. The Supernus Pharmaceuticals Inc shares were sold for 18.6% higher than average price of previous purchases. This sale made a profit of USD 4,491 The average price that the ETF previously sold SUPN share for is USD 36.4483 so the ETF has sold 596 shares on 2026-01-30 at a higher price than the previous selling average. |
| VRDN - Viridian Therapeutics Inc | SELL | -872 @ USD 33 | USD -28,776 | The ETF sold 872 shares of VRDN on 2026-01-30. The shares were previously bought for an average price of USD 30.5932. The Viridian Therapeutics Inc shares were sold for 7.9% higher than average price of previous purchases. This sale made a profit of USD 2,099 The average price that the ETF previously sold VRDN share for is USD 26.6367 so the ETF has sold 872 shares on 2026-01-30 at a higher price than the previous selling average. |
| VCYT - Veracyte Inc | SELL | -770 @ USD 38.08 | USD -29,322 | The ETF sold 770 shares of VCYT on 2026-01-30. The shares were previously bought for an average price of USD 36.6113. The Veracyte Inc shares were sold for 4.0% higher than average price of previous purchases. This sale made a profit of USD 1,131 The average price that the ETF previously sold VCYT share for is USD 34.9018 so the ETF has sold 770 shares on 2026-01-30 at a higher price than the previous selling average. |
| BEAM - Beam Therapeutics Inc | SELL | -1,066 @ USD 27.62 | USD -29,443 | The ETF sold 1066 shares of BEAM on 2026-01-30. The shares were previously bought for an average price of USD 19.259. The Beam Therapeutics Inc shares were sold for 43.4% higher than average price of previous purchases. This sale made a profit of USD 8,913 The average price that the ETF previously sold BEAM share for is USD 21.8004 so the ETF has sold 1066 shares on 2026-01-30 at a higher price than the previous selling average. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -1,592 @ USD 18.5 | USD -29,452 | The ETF sold 1592 shares of ADPT on 2026-01-30. The shares were previously bought for an average price of USD 7.61991. The Adaptive Biotechnologies Corp shares were sold for 142.8% higher than average price of previous purchases. This sale made a profit of USD 17,321 The average price that the ETF previously sold ADPT share for is USD 9.24486 so the ETF has sold 1592 shares on 2026-01-30 at a higher price than the previous selling average. |
| IDYA - Ideaya Biosciences Inc | SELL | -924 @ USD 32.19 | USD -29,744 | The ETF sold 924 shares of IDYA on 2026-01-30. The shares were previously bought for an average price of USD 24.8278. The Ideaya Biosciences Inc shares were sold for 29.7% higher than average price of previous purchases. This sale made a profit of USD 6,803 The average price that the ETF previously sold IDYA share for is USD 23.5288 so the ETF has sold 924 shares on 2026-01-30 at a higher price than the previous selling average. |
| ACLX - Arcellx Inc | SELL | -440 @ USD 68.31 | USD -30,056 | The ETF sold 440 shares of ACLX on 2026-01-30. The shares were previously bought for an average price of USD 65.004. The Arcellx Inc shares were sold for 5.1% higher than average price of previous purchases. This sale made a profit of USD 1,455 The average price that the ETF previously sold ACLX share for is USD 71.2976 which is higher than the selling price of USD 68.31 on 2026-01-30. |
| BANB.SW - | SELL | -336 @ CHF 90.9032 | CHF -30,543 | The ETF sold 336 shares of BANB.SW on 2026-01-30. The shares were previously bought for an average price of CHF 70.3497. The shares were sold for 29.2% higher than average price of previous purchases. This sale made a profit of CHF 6,906 The average price that the ETF previously sold BANB.SW share for is CHF 67.7114 so the ETF has sold 336 shares on 2026-01-30 at a higher price than the previous selling average. |
| CPRX - Catalyst Pharmaceuticals Inc | SELL | -1,290 @ USD 24.3 | USD -31,347 | The ETF sold 1290 shares of CPRX on 2026-01-30. The shares were previously bought for an average price of USD 22.5395. The Catalyst Pharmaceuticals Inc shares were sold for 7.8% higher than average price of previous purchases. This sale made a profit of USD 2,271 The average price that the ETF previously sold CPRX share for is USD 22.5381 so the ETF has sold 1290 shares on 2026-01-30 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -1,302 @ USD 25.13 | USD -32,719 | The ETF sold 1302 shares of ACAD on 2026-01-30. The shares were previously bought for an average price of USD 21.2784. The ACADIA Pharmaceuticals Inc shares were sold for 18.1% higher than average price of previous purchases. This sale made a profit of USD 5,015 The average price that the ETF previously sold ACAD share for is USD 18.5762 so the ETF has sold 1302 shares on 2026-01-30 at a higher price than the previous selling average. |
| CGON - CG Oncology, Inc. Common stock | SELL | -648 @ USD 52.05 | USD -33,728 | The ETF sold 648 shares of CGON on 2026-01-30. The shares were previously bought for an average price of USD 43.3614. The CG Oncology, Inc. Common stock shares were sold for 20.0% higher than average price of previous purchases. This sale made a profit of USD 5,630 The average price that the ETF previously sold CGON share for is USD 36.9733 so the ETF has sold 648 shares on 2026-01-30 at a higher price than the previous selling average. |
| LIVN - LivaNova PLC | SELL | -576 @ USD 65.71 | USD -37,849 | The ETF sold 576 shares of LIVN on 2026-01-30. The shares were previously bought for an average price of USD 53.1592. The LivaNova PLC shares were sold for 23.6% higher than average price of previous purchases. This sale made a profit of USD 7,229 The average price that the ETF previously sold LIVN share for is USD 46.929 so the ETF has sold 576 shares on 2026-01-30 at a higher price than the previous selling average. |
| SECT-B.ST - | SELL | -1,538 @ SEK 24.875 | SEK -38,258 | The ETF sold 1538 shares of SECT-B.ST on 2026-01-30. The shares were previously bought for an average price of SEK 27.5618. The shares were sold for -9.7% lower than average price of previous purchases. This resulted in an overall loss of SEK 4,132 The average price that the ETF previously sold SECT-B.ST share for is SEK 28.6111 which is higher than the selling price of SEK 24.875 on 2026-01-30. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -202 @ USD 192.1 | USD -38,804 | The ETF sold 202 shares of LGND on 2026-01-30. The shares were previously bought for an average price of USD 133.982. The Ligand Pharmaceuticals Incorporated shares were sold for 43.4% higher than average price of previous purchases. This sale made a profit of USD 11,740 The average price that the ETF previously sold LGND share for is USD 128.503 so the ETF has sold 202 shares on 2026-01-30 at a higher price than the previous selling average. |
| 7747.T - Asahi Intecc Co., Ltd. | SELL | -2,600 @ JPY 16.6602 | JPY -43,317 | The ETF sold 2600 shares of 7747.T on 2026-01-30. The shares were previously bought for an average price of JPY 17.2752. The Asahi Intecc Co., Ltd. shares were sold for -3.6% lower than average price of previous purchases. This resulted in an overall loss of JPY 1,599 The average price that the ETF previously sold 7747.T share for is JPY 16.2907 so the ETF has sold 2600 shares on 2026-01-30 at a higher price than the previous selling average. |
| TGTX - TG Therapeutics Inc | SELL | -1,524 @ USD 29.43 | USD -44,851 | The ETF sold 1524 shares of TGTX on 2026-01-30. The shares were previously bought for an average price of USD 32.8137. The TG Therapeutics Inc shares were sold for -10.3% lower than average price of previous purchases. This resulted in an overall loss of USD 5,157 The average price that the ETF previously sold TGTX share for is USD 33.8871 which is higher than the selling price of USD 29.43 on 2026-01-30. |
| LNTH - Lantheus Holdings Inc | SELL | -724 @ USD 66.92 | USD -48,450 | The ETF sold 724 shares of LNTH on 2026-01-30. The shares were previously bought for an average price of USD 75.2336. The Lantheus Holdings Inc shares were sold for -11.1% lower than average price of previous purchases. This resulted in an overall loss of USD 6,019 The average price that the ETF previously sold LNTH share for is USD 84.8465 which is higher than the selling price of USD 66.92 on 2026-01-30. |
| SFZN.SW - | SELL | -416 @ CHF 123.239 | CHF -51,267 | The ETF sold 416 shares of SFZN.SW on 2026-01-30. The shares were previously bought for an average price of CHF 123.113. The shares were sold for 0.1% higher than average price of previous purchases. This sale made a profit of CHF 52 The average price that the ETF previously sold SFZN.SW share for is CHF 239.028 which is higher than the selling price of CHF 123.239 on 2026-01-30. |
| 6869.T - Sysmex Corporation | SELL | -5,400 @ JPY 9.50992 | JPY -51,354 | The ETF sold 5400 shares of 6869.T on 2026-01-30. The shares were previously bought for an average price of JPY 13.9292. The Sysmex Corporation shares were sold for -31.7% lower than average price of previous purchases. This resulted in an overall loss of JPY 23,864 The average price that the ETF previously sold 6869.T share for is JPY 17.0458 which is higher than the selling price of JPY 9.50992 on 2026-01-30. |
| 298380.KQ - ABL Bio Inc. | SELL | -376 @ KRW 137.349 | KRW -51,643 | The ETF sold 376 shares of 298380.KQ on 2026-01-30. The shares were previously bought for an average price of KRW 108.523. The ABL Bio Inc. shares were sold for 26.6% higher than average price of previous purchases. This sale made a profit of KRW 10,839 The average price that the ETF previously sold 298380.KQ share for is KRW 47.6846 so the ETF has sold 376 shares on 2026-01-30 at a higher price than the previous selling average. |
| MMS - LYXETFETUSITETFP | SELL | -594 @ USD 94.44 | USD -56,097 | The ETF sold 594 shares of MMS on 2026-01-30. The shares were previously bought for an average price of USD 79.4418. The LYXETFETUSITETFP shares were sold for 18.9% higher than average price of previous purchases. This sale made a profit of USD 8,909 The average price that the ETF previously sold MMS share for is USD 73.3409 so the ETF has sold 594 shares on 2026-01-30 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -1,748 @ USD 33.89 | USD -59,240 | The ETF sold 1748 shares of ALKS on 2026-01-30. The shares were previously bought for an average price of USD 30.3174. The Alkermes Plc shares were sold for 11.8% higher than average price of previous purchases. This sale made a profit of USD 6,245 The average price that the ETF previously sold ALKS share for is USD 29.3631 so the ETF has sold 1748 shares on 2026-01-30 at a higher price than the previous selling average. |
| BIM.PA - BioMerieux | SELL | -514 @ EUR 116.348 | EUR -59,803 | The ETF sold 514 shares of BIM.PA on 2026-01-30. The shares were previously bought for an average price of EUR 123.369. The BioMerieux shares were sold for -5.7% lower than average price of previous purchases. This resulted in an overall loss of EUR 3,609 The average price that the ETF previously sold BIM.PA share for is EUR 123.502 which is higher than the selling price of EUR 116.348 on 2026-01-30. |
| IPN.PA - Ipsen SA | SELL | -382 @ EUR 163.696 | EUR -62,532 | The ETF sold 382 shares of IPN.PA on 2026-01-30. The shares were previously bought for an average price of EUR 128.01. The Ipsen SA shares were sold for 27.9% higher than average price of previous purchases. This sale made a profit of EUR 13,632 The average price that the ETF previously sold IPN.PA share for is EUR 119.811 so the ETF has sold 382 shares on 2026-01-30 at a higher price than the previous selling average. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -612 @ USD 102.52 | USD -62,742 | The ETF sold 612 shares of RYTM on 2026-01-30. The shares were previously bought for an average price of USD 75.0313. The Rhythm Pharmaceuticals Inc shares were sold for 36.6% higher than average price of previous purchases. This sale made a profit of USD 16,823 The average price that the ETF previously sold RYTM share for is USD 69.2349 so the ETF has sold 612 shares on 2026-01-30 at a higher price than the previous selling average. |
| PTCT - PTC Therapeutics Inc | SELL | -836 @ USD 75.53 | USD -63,143 | The ETF sold 836 shares of PTCT on 2026-01-30. The shares were previously bought for an average price of USD 61.3082. The PTC Therapeutics Inc shares were sold for 23.2% higher than average price of previous purchases. This sale made a profit of USD 11,889 The average price that the ETF previously sold PTCT share for is USD 51.9372 so the ETF has sold 836 shares on 2026-01-30 at a higher price than the previous selling average. |
| BIO - Bio-Rad Laboratories Inc | SELL | -222 @ USD 293.7 | USD -65,201 | The ETF sold 222 shares of BIO on 2026-01-30. The shares were previously bought for an average price of USD 294.526. The Bio-Rad Laboratories Inc shares were sold for -0.3% lower than average price of previous purchases. This resulted in an overall loss of USD 183 The average price that the ETF previously sold BIO share for is USD 271.499 so the ETF has sold 222 shares on 2026-01-30 at a higher price than the previous selling average. |
| BIO - Biotest Aktiengesellschaft | SELL | -222 @ USD 293.7 | USD -65,201 | The ETF sold 222 shares of BIO on 2026-01-30. The shares were previously bought for an average price of USD 294.526. The Biotest Aktiengesellschaft shares were sold for -0.3% lower than average price of previous purchases. This resulted in an overall loss of USD 183 The average price that the ETF previously sold BIO share for is USD 271.499 so the ETF has sold 222 shares on 2026-01-30 at a higher price than the previous selling average. |
| PRAX - Praxis Precision Medicines Inc | SELL | -216 @ USD 314 | USD -67,824 | The ETF sold 216 shares of PRAX on 2026-01-30. The shares were previously bought for an average price of USD 230.084. The Praxis Precision Medicines Inc shares were sold for 36.5% higher than average price of previous purchases. This sale made a profit of USD 18,126 The average price that the ETF previously sold PRAX share for is USD 197.375 so the ETF has sold 216 shares on 2026-01-30 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -404 @ USD 184.25 | USD -74,437 | The ETF sold 404 shares of AXSM on 2026-01-30. The shares were previously bought for an average price of USD 131.729. The Axsome Therapeutics Inc shares were sold for 39.9% higher than average price of previous purchases. This sale made a profit of USD 21,218 The average price that the ETF previously sold AXSM share for is USD 111.479 so the ETF has sold 404 shares on 2026-01-30 at a higher price than the previous selling average. |
| SRT3.DE - Sartorius AG | SELL | -266 @ EUR 280.519 | EUR -74,618 | The ETF sold 266 shares of SRT3.DE on 2026-01-30. The shares were previously bought for an average price of EUR 260.58. The Sartorius AG shares were sold for 7.7% higher than average price of previous purchases. This sale made a profit of EUR 5,304 The average price that the ETF previously sold SRT3.DE share for is EUR 244.773 so the ETF has sold 266 shares on 2026-01-30 at a higher price than the previous selling average. |
| PME.AX - | SELL | -592 @ AUD 128.985 | AUD -76,359 | The ETF sold 592 shares of PME.AX on 2026-01-30. The shares were previously bought for an average price of AUD 159.981. The shares were sold for -19.4% lower than average price of previous purchases. This resulted in an overall loss of AUD 18,350 The average price that the ETF previously sold PME.AX share for is AUD 149.51 which is higher than the selling price of AUD 128.985 on 2026-01-30. |
| 7701.T - Shimadzu Corporation | SELL | -3,000 @ JPY 26.9934 | JPY -80,980 | The ETF sold 3000 shares of 7701.T on 2026-01-30. The shares were previously bought for an average price of JPY 26.618. The Shimadzu Corporation shares were sold for 1.4% higher than average price of previous purchases. This sale made a profit of JPY 1,126 The average price that the ETF previously sold 7701.T share for is JPY 26.1793 so the ETF has sold 3000 shares on 2026-01-30 at a higher price than the previous selling average. |
| RGEN - Repligen Corporation | SELL | -552 @ USD 149.37 | USD -82,452 | The ETF sold 552 shares of RGEN on 2026-01-30. The shares were previously bought for an average price of USD 150.813. The Repligen Corporation shares were sold for -1.0% lower than average price of previous purchases. This resulted in an overall loss of USD 797 The average price that the ETF previously sold RGEN share for is USD 138.03 so the ETF has sold 552 shares on 2026-01-30 at a higher price than the previous selling average. |
| 4523.T - Eisai Co., Ltd. | SELL | -3,000 @ JPY 27.9463 | JPY -83,839 | The ETF sold 3000 shares of 4523.T on 2026-01-30. The shares were previously bought for an average price of JPY 28.6683. The Eisai Co., Ltd. shares were sold for -2.5% lower than average price of previous purchases. This resulted in an overall loss of JPY 2,166 The average price that the ETF previously sold 4523.T share for is JPY 28.5874 which is higher than the selling price of JPY 27.9463 on 2026-01-30. |
| HALO - Halozyme Therapeutics Inc | SELL | -1,298 @ USD 71.71 | USD -93,080 | The ETF sold 1298 shares of HALO on 2026-01-30. The shares were previously bought for an average price of USD 63.1165. The Halozyme Therapeutics Inc shares were sold for 13.6% higher than average price of previous purchases. This sale made a profit of USD 11,154 The average price that the ETF previously sold HALO share for is USD 55.767 so the ETF has sold 1298 shares on 2026-01-30 at a higher price than the previous selling average. |
| ABT - Abbott Laboratories | SELL | -966 @ USD 109.3 | USD -105,584 | The ETF sold 966 shares of ABT on 2026-01-30. The shares were previously bought for an average price of USD 124.137. The Abbott Laboratories shares were sold for -12.0% lower than average price of previous purchases. This resulted in an overall loss of USD 14,333 The average price that the ETF previously sold ABT share for is USD 128.789 which is higher than the selling price of USD 109.3 on 2026-01-30. |
| TECH - Bio-Techne Corp | SELL | -1,650 @ USD 64.09 | USD -105,749 | The ETF sold 1650 shares of TECH on 2026-01-30. The shares were previously bought for an average price of USD 60.2995. The Bio-Techne Corp shares were sold for 6.3% higher than average price of previous purchases. This sale made a profit of USD 6,254 The average price that the ETF previously sold TECH share for is USD 58.8812 so the ETF has sold 1650 shares on 2026-01-30 at a higher price than the previous selling average. |
| CRL - Creightons Plc | SELL | -516 @ USD 210.48 | USD -108,608 | The ETF sold 516 shares of CRL on 2026-01-30. The shares were previously bought for an average price of USD 177.153. The Creightons Plc shares were sold for 18.8% higher than average price of previous purchases. This sale made a profit of USD 17,197 The average price that the ETF previously sold CRL share for is USD 158.346 so the ETF has sold 516 shares on 2026-01-30 at a higher price than the previous selling average. |
| PODD - Insulet Corporation | SELL | -434 @ USD 255.81 | USD -111,022 | The ETF sold 434 shares of PODD on 2026-01-30. The shares were previously bought for an average price of USD 283.798. The Insulet Corporation shares were sold for -9.9% lower than average price of previous purchases. This resulted in an overall loss of USD 12,147 The average price that the ETF previously sold PODD share for is USD 292.692 which is higher than the selling price of USD 255.81 on 2026-01-30. |
| DXCM - DexCom Inc | SELL | -1,526 @ USD 73.04 | USD -111,459 | The ETF sold 1526 shares of DXCM on 2026-01-30. The shares were previously bought for an average price of USD 78.1176. The DexCom Inc shares were sold for -6.5% lower than average price of previous purchases. This resulted in an overall loss of USD 7,748 The average price that the ETF previously sold DXCM share for is USD 72.9654 so the ETF has sold 1526 shares on 2026-01-30 at a higher price than the previous selling average. |
| EXEL - Exelixis Inc | SELL | -2,872 @ USD 41.36 | USD -118,786 | The ETF sold 2872 shares of EXEL on 2026-01-30. The shares were previously bought for an average price of USD 39.8111. The Exelixis Inc shares were sold for 3.9% higher than average price of previous purchases. This sale made a profit of USD 4,448 The average price that the ETF previously sold EXEL share for is USD 39.1199 so the ETF has sold 2872 shares on 2026-01-30 at a higher price than the previous selling average. |
| BSX - Boston Scientific Corporation | SELL | -1,304 @ USD 93.53 | USD -121,963 | The ETF sold 1304 shares of BSX on 2026-01-30. The shares were previously bought for an average price of USD 97.0625. The Boston Scientific Corporation shares were sold for -3.6% lower than average price of previous purchases. This resulted in an overall loss of USD 4,606 The average price that the ETF previously sold BSX share for is USD 98.5378 which is higher than the selling price of USD 93.53 on 2026-01-30. |
| BSX - MULSTRXSSXIMETFP | SELL | -1,304 @ USD 93.53 | USD -121,963 | The ETF sold 1304 shares of BSX on 2026-01-30. The shares were previously bought for an average price of USD 97.0625. The MULSTRXSSXIMETFP shares were sold for -3.6% lower than average price of previous purchases. This resulted in an overall loss of USD 4,606 The average price that the ETF previously sold BSX share for is USD 98.5378 which is higher than the selling price of USD 93.53 on 2026-01-30. |
| ISRG - Intuitive Surgical Inc | SELL | -244 @ USD 504.22 | USD -123,030 | The ETF sold 244 shares of ISRG on 2026-01-30. The shares were previously bought for an average price of USD 541.916. The Intuitive Surgical Inc shares were sold for -7.0% lower than average price of previous purchases. This resulted in an overall loss of USD 9,198 The average price that the ETF previously sold ISRG share for is USD 521.027 which is higher than the selling price of USD 504.22 on 2026-01-30. |
| LONN.SW - | SELL | -184 @ CHF 681.774 | CHF -125,446 | The ETF sold 184 shares of LONN.SW on 2026-01-30. The shares were previously bought for an average price of CHF 651.316. The shares were sold for 4.7% higher than average price of previous purchases. This sale made a profit of CHF 5,604 The average price that the ETF previously sold LONN.SW share for is CHF 663.678 so the ETF has sold 184 shares on 2026-01-30 at a higher price than the previous selling average. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | SELL | -110 @ KRW 1212.31 | KRW -133,354 | The ETF sold 110 shares of 207940.KS on 2026-01-30. The shares were previously bought for an average price of KRW 846.854. The SAMSUNG BIOLOGICS LTD shares were sold for 43.2% higher than average price of previous purchases. This sale made a profit of KRW 40,200 The average price that the ETF previously sold 207940.KS share for is KRW 966.117 so the ETF has sold 110 shares on 2026-01-30 at a higher price than the previous selling average. |
| RVTY - Revvity Inc. | SELL | -1,240 @ USD 108.8 | USD -134,912 | The ETF sold 1240 shares of RVTY on 2026-01-30. The shares were previously bought for an average price of USD 102.102. The Revvity Inc. shares were sold for 6.6% higher than average price of previous purchases. This sale made a profit of USD 8,306 The average price that the ETF previously sold RVTY share for is USD 96.4967 so the ETF has sold 1240 shares on 2026-01-30 at a higher price than the previous selling average. |
| EW - Edwards Lifesciences Corp | SELL | -1,708 @ USD 81.36 | USD -138,963 | The ETF sold 1708 shares of EW on 2026-01-30. The shares were previously bought for an average price of USD 75.6991. The Edwards Lifesciences Corp shares were sold for 7.5% higher than average price of previous purchases. This sale made a profit of USD 9,669 The average price that the ETF previously sold EW share for is USD 74.5852 so the ETF has sold 1708 shares on 2026-01-30 at a higher price than the previous selling average. |
| DHR - Danaher Corporation | SELL | -638 @ USD 218.89 | USD -139,652 | The ETF sold 638 shares of DHR on 2026-01-30. The shares were previously bought for an average price of USD 202.721. The Danaher Corporation shares were sold for 8.0% higher than average price of previous purchases. This sale made a profit of USD 10,316 The average price that the ETF previously sold DHR share for is USD 212.152 so the ETF has sold 638 shares on 2026-01-30 at a higher price than the previous selling average. |
| DHR - Danaher Corporation | SELL | -638 @ USD 218.89 | USD -139,652 | The ETF sold 638 shares of DHR on 2026-01-30. The shares were previously bought for an average price of USD 202.721. The Danaher Corporation shares were sold for 8.0% higher than average price of previous purchases. This sale made a profit of USD 10,316 The average price that the ETF previously sold DHR share for is USD 212.152 so the ETF has sold 638 shares on 2026-01-30 at a higher price than the previous selling average. |
| PFE - Pfizer Inc | SELL | -5,330 @ USD 26.44 | USD -140,925 | The ETF sold 5330 shares of PFE on 2026-01-30. The shares were previously bought for an average price of USD 24.4485. The Pfizer Inc shares were sold for 8.1% higher than average price of previous purchases. This sale made a profit of USD 10,615 The average price that the ETF previously sold PFE share for is USD 24.4674 so the ETF has sold 5330 shares on 2026-01-30 at a higher price than the previous selling average. |
| NBIX - Neurocrine Biosciences Inc | SELL | -1,038 @ USD 136.06 | USD -141,230 | The ETF sold 1038 shares of NBIX on 2026-01-30. The shares were previously bought for an average price of USD 129.339. The Neurocrine Biosciences Inc shares were sold for 5.2% higher than average price of previous purchases. This sale made a profit of USD 6,976 The average price that the ETF previously sold NBIX share for is USD 120.037 so the ETF has sold 1038 shares on 2026-01-30 at a higher price than the previous selling average. |
| BMY - Bloomsbury Publishing Plc | SELL | -2,590 @ USD 55.05 | USD -142,580 | The ETF sold 2590 shares of BMY on 2026-01-30. The shares were previously bought for an average price of USD 53.6947. The Bloomsbury Publishing Plc shares were sold for 2.5% higher than average price of previous purchases. This sale made a profit of USD 3,510 The average price that the ETF previously sold BMY share for is USD 50.8988 so the ETF has sold 2590 shares on 2026-01-30 at a higher price than the previous selling average. |
| A - Agilent Technologies Inc | SELL | -1,074 @ USD 133.85 | USD -143,755 | The ETF sold 1074 shares of A on 2026-01-30. The shares were previously bought for an average price of USD 124.545. The Agilent Technologies Inc shares were sold for 7.5% higher than average price of previous purchases. This sale made a profit of USD 9,994 The average price that the ETF previously sold A share for is USD 124.037 so the ETF has sold 1074 shares on 2026-01-30 at a higher price than the previous selling average. |
| MEDP - Medpace Holdings Inc | SELL | -252 @ USD 582.48 | USD -146,785 | The ETF sold 252 shares of MEDP on 2026-01-30. The shares were previously bought for an average price of USD 424.793. The Medpace Holdings Inc shares were sold for 37.1% higher than average price of previous purchases. This sale made a profit of USD 39,737 The average price that the ETF previously sold MEDP share for is USD 366.594 so the ETF has sold 252 shares on 2026-01-30 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -1,304 @ USD 114.04 | USD -148,708 | The ETF sold 1304 shares of GH on 2026-01-30. The shares were previously bought for an average price of USD 67.3123. The Guardant Health Inc shares were sold for 69.4% higher than average price of previous purchases. This sale made a profit of USD 60,933 The average price that the ETF previously sold GH share for is USD 50.1233 so the ETF has sold 1304 shares on 2026-01-30 at a higher price than the previous selling average. |
| HOLX - Hologic Inc | SELL | -1,988 @ USD 74.93 | USD -148,961 | The ETF sold 1988 shares of HOLX on 2026-01-30. The shares were previously bought for an average price of USD 67.2756. The Hologic Inc shares were sold for 11.4% higher than average price of previous purchases. This sale made a profit of USD 15,217 The average price that the ETF previously sold HOLX share for is USD 67.725 so the ETF has sold 1988 shares on 2026-01-30 at a higher price than the previous selling average. |
| AMGN - Amgen Inc | SELL | -440 @ USD 341.88 | USD -150,427 | The ETF sold 440 shares of AMGN on 2026-01-30. The shares were previously bought for an average price of USD 303.143. The Amgen Inc shares were sold for 12.8% higher than average price of previous purchases. This sale made a profit of USD 17,044 The average price that the ETF previously sold AMGN share for is USD 295.68 so the ETF has sold 440 shares on 2026-01-30 at a higher price than the previous selling average. |
| MDT - Medtronic PLC | SELL | -1,472 @ USD 102.96 | USD -151,557 | The ETF sold 1472 shares of MDT on 2026-01-30. The shares were previously bought for an average price of USD 92.2389. The Medtronic PLC shares were sold for 11.6% higher than average price of previous purchases. This sale made a profit of USD 15,781 The average price that the ETF previously sold MDT share for is USD 88.0238 so the ETF has sold 1472 shares on 2026-01-30 at a higher price than the previous selling average. |
| ABBV - AbbVie Inc | SELL | -682 @ USD 223.01 | USD -152,093 | The ETF sold 682 shares of ABBV on 2026-01-30. The shares were previously bought for an average price of USD 208.051. The AbbVie Inc shares were sold for 7.2% higher than average price of previous purchases. This sale made a profit of USD 10,202 The average price that the ETF previously sold ABBV share for is USD 190.578 so the ETF has sold 682 shares on 2026-01-30 at a higher price than the previous selling average. |
| 068270.KS - CELLTRION INC | SELL | -1,088 @ KRW 145.894 | KRW -158,733 | The ETF sold 1088 shares of 068270.KS on 2026-01-30. The shares were previously bought for an average price of KRW 123.544. The CELLTRION INC shares were sold for 18.1% higher than average price of previous purchases. This sale made a profit of KRW 24,317 The average price that the ETF previously sold 068270.KS share for is KRW 120.495 so the ETF has sold 1088 shares on 2026-01-30 at a higher price than the previous selling average. |
| NOVN.SW - | SELL | -1,090 @ CHF 148.847 | CHF -162,243 | The ETF sold 1090 shares of NOVN.SW on 2026-01-30. The shares were previously bought for an average price of CHF 120.927. The shares were sold for 23.1% higher than average price of previous purchases. This sale made a profit of CHF 30,433 The average price that the ETF previously sold NOVN.SW share for is CHF 113.719 so the ETF has sold 1090 shares on 2026-01-30 at a higher price than the previous selling average. |
| GSK.L - GlaxoSmithKline PLC | SELL | -6,350 @ GBP 25.7503 | GBP -163,514 | The ETF sold 6350 shares of GSK.L on 2026-01-30. The shares were previously bought for an average price of GBP 20.3485. The GlaxoSmithKline PLC shares were sold for 26.5% higher than average price of previous purchases. This sale made a profit of GBP 34,301 The average price that the ETF previously sold GSK.L share for is GBP 19.1298 so the ETF has sold 6350 shares on 2026-01-30 at a higher price than the previous selling average. |
| GILD - Guild Esports Plc | SELL | -1,176 @ USD 141.95 | USD -166,933 | The ETF sold 1176 shares of GILD on 2026-01-30. The shares were previously bought for an average price of USD 111.127. The Guild Esports Plc shares were sold for 27.7% higher than average price of previous purchases. This sale made a profit of USD 36,248 The average price that the ETF previously sold GILD share for is USD 106.62 so the ETF has sold 1176 shares on 2026-01-30 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -954 @ USD 179.89 | USD -171,615 | The ETF sold 954 shares of BIIB on 2026-01-30. The shares were previously bought for an average price of USD 133.158. The Biogen Inc shares were sold for 35.1% higher than average price of previous purchases. This sale made a profit of USD 44,582 The average price that the ETF previously sold BIIB share for is USD 146.427 so the ETF has sold 954 shares on 2026-01-30 at a higher price than the previous selling average. |
| ROG.SW - | SELL | -378 @ CHF 455.425 | CHF -172,151 | The ETF sold 378 shares of ROG.SW on 2026-01-30. The shares were previously bought for an average price of CHF 347.97. The shares were sold for 30.9% higher than average price of previous purchases. This sale made a profit of CHF 40,618 The average price that the ETF previously sold ROG.SW share for is CHF 320.023 so the ETF has sold 378 shares on 2026-01-30 at a higher price than the previous selling average. |
| MRK - Marks Electrical Group PLC | SELL | -1,590 @ USD 110.27 | USD -175,329 | The ETF sold 1590 shares of MRK on 2026-01-30. The shares were previously bought for an average price of USD 82.3939. The Marks Electrical Group PLC shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 44,323 The average price that the ETF previously sold MRK share for is USD 90.2468 so the ETF has sold 1590 shares on 2026-01-30 at a higher price than the previous selling average. |
| MRK - Merck & Company Inc | SELL | -1,590 @ USD 110.27 | USD -175,329 | The ETF sold 1590 shares of MRK on 2026-01-30. The shares were previously bought for an average price of USD 82.3939. The Merck & Company Inc shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 44,323 The average price that the ETF previously sold MRK share for is USD 90.2468 so the ETF has sold 1590 shares on 2026-01-30 at a higher price than the previous selling average. |
| MRNA - Moderna Inc | SELL | -4,070 @ USD 44.07 | USD -179,365 | The ETF sold 4070 shares of MRNA on 2026-01-30. The shares were previously bought for an average price of USD 26.3228. The Moderna Inc shares were sold for 67.4% higher than average price of previous purchases. This sale made a profit of USD 72,231 The average price that the ETF previously sold MRNA share for is USD 31.0535 so the ETF has sold 4070 shares on 2026-01-30 at a higher price than the previous selling average. |
| TMO - Time Out Group plc | SELL | -312 @ USD 578.61 | USD -180,526 | The ETF sold 312 shares of TMO on 2026-01-30. The shares were previously bought for an average price of USD 432.097. The Time Out Group plc shares were sold for 33.9% higher than average price of previous purchases. This sale made a profit of USD 45,712 The average price that the ETF previously sold TMO share for is USD 497.384 so the ETF has sold 312 shares on 2026-01-30 at a higher price than the previous selling average. |
| NTRA - Natera Inc | SELL | -784 @ USD 231.14 | USD -181,214 | The ETF sold 784 shares of NTRA on 2026-01-30. The shares were previously bought for an average price of USD 190.06. The Natera Inc shares were sold for 21.6% higher than average price of previous purchases. This sale made a profit of USD 32,207 The average price that the ETF previously sold NTRA share for is USD 167.391 so the ETF has sold 784 shares on 2026-01-30 at a higher price than the previous selling average. |
| GMAB.CO - | SELL | -564 @ DKK 322.118 | DKK -181,675 | The ETF sold 564 shares of GMAB.CO on 2026-01-30. The shares were previously bought for an average price of DKK 232.387. The shares were sold for 38.6% higher than average price of previous purchases. This sale made a profit of DKK 50,608 The average price that the ETF previously sold GMAB.CO share for is DKK 230.216 so the ETF has sold 564 shares on 2026-01-30 at a higher price than the previous selling average. |
| IQV - IQVIA Holdings Inc | SELL | -810 @ USD 230.15 | USD -186,422 | The ETF sold 810 shares of IQV on 2026-01-30. The shares were previously bought for an average price of USD 167.812. The IQVIA Holdings Inc shares were sold for 37.1% higher than average price of previous purchases. This sale made a profit of USD 50,494 The average price that the ETF previously sold IQV share for is USD 184.32 so the ETF has sold 810 shares on 2026-01-30 at a higher price than the previous selling average. |
| JNJ - Johnson & Johnson | SELL | -826 @ USD 227.25 | USD -187,709 | The ETF sold 826 shares of JNJ on 2026-01-30. The shares were previously bought for an average price of USD 182.297. The Johnson & Johnson shares were sold for 24.7% higher than average price of previous purchases. This sale made a profit of USD 37,131 The average price that the ETF previously sold JNJ share for is USD 162.968 so the ETF has sold 826 shares on 2026-01-30 at a higher price than the previous selling average. |
| EXAS - EXACT Sciences Corporation | SELL | -1,986 @ USD 102.34 | USD -203,247 | The ETF sold 1986 shares of EXAS on 2026-01-30. The shares were previously bought for an average price of USD 70.5974. The EXACT Sciences Corporation shares were sold for 45.0% higher than average price of previous purchases. This sale made a profit of USD 63,041 The average price that the ETF previously sold EXAS share for is USD 59.0275 so the ETF has sold 1986 shares on 2026-01-30 at a higher price than the previous selling average. |
| UCB.BR - UCB SA | SELL | -688 @ EUR 303.837 | EUR -209,040 | The ETF sold 688 shares of UCB.BR on 2026-01-30. The shares were previously bought for an average price of EUR 226.575. The UCB SA shares were sold for 34.1% higher than average price of previous purchases. This sale made a profit of EUR 53,156 The average price that the ETF previously sold UCB.BR share for is EUR 188.249 so the ETF has sold 688 shares on 2026-01-30 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -1,470 @ USD 144.81 | USD -212,871 | The ETF sold 1470 shares of ILMN on 2026-01-30. The shares were previously bought for an average price of USD 99.2305. The Illumina Inc shares were sold for 45.9% higher than average price of previous purchases. This sale made a profit of USD 67,002 The average price that the ETF previously sold ILMN share for is USD 106.591 so the ETF has sold 1470 shares on 2026-01-30 at a higher price than the previous selling average. |